Cumberland Pharmaceuticals Inc. (CPIX)
USD 2.34
(10.38%)
USD 2.34
(10.38%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 18.42 Million USD | -12.07% |
| 2022 | 20.95 Million USD | 30.51% |
| 2021 | 16.05 Million USD | -5.95% |
| 2020 | 17.07 Million USD | -20.56% |
| 2019 | 21.49 Million USD | 7.48% |
| 2018 | 20 Million USD | 104.08% |
| 2017 | 9.8 Million USD | 139.02% |
| 2016 | 4.1 Million USD | 141.18% |
| 2015 | 1.7 Million USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | -100.0% |
| 2012 | 4.35 Million USD | -19.83% |
| 2011 | 5.43 Million USD | -30.3% |
| 2010 | 7.8 Million USD | -61.29% |
| 2009 | 20.15 Million USD | 195.28% |
| 2008 | 6.82 Million USD | 67.47% |
| 2007 | 4.07 Million USD | -24.65% |
| 2006 | 5.4 Million USD | 1823.58% |
| 2005 | 281.2 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 21.64 Million USD | 17.46% |
| 2024 Q2 | 21.56 Million USD | -0.36% |
| 2023 Q4 | 18.42 Million USD | -1.17% |
| 2023 Q3 | 18.64 Million USD | -1.58% |
| 2023 Q1 | 20.77 Million USD | -0.86% |
| 2023 Q2 | 18.94 Million USD | -8.82% |
| 2023 FY | 18.42 Million USD | -12.07% |
| 2022 FY | 20.95 Million USD | 30.51% |
| 2022 Q1 | 20.78 Million USD | 29.45% |
| 2022 Q2 | 19.51 Million USD | -6.14% |
| 2022 Q3 | 17.92 Million USD | -8.11% |
| 2022 Q4 | 20.95 Million USD | 16.9% |
| 2021 FY | 16.05 Million USD | -5.95% |
| 2021 Q2 | 15.58 Million USD | -7.43% |
| 2021 Q4 | 16.05 Million USD | -1.62% |
| 2021 Q1 | 16.83 Million USD | -1.44% |
| 2021 Q3 | 16.32 Million USD | 4.77% |
| 2020 Q3 | 19.31 Million USD | -1.19% |
| 2020 Q4 | 17.07 Million USD | -11.59% |
| 2020 FY | 17.07 Million USD | -20.56% |
| 2020 Q1 | 21.27 Million USD | -1.03% |
| 2020 Q2 | 19.54 Million USD | -8.12% |
| 2019 FY | 21.49 Million USD | 7.48% |
| 2019 Q4 | 21.49 Million USD | 7.48% |
| 2019 Q2 | 20 Million USD | 0.0% |
| 2019 Q3 | 20 Million USD | 0.0% |
| 2019 Q1 | 20 Million USD | 0.0% |
| 2018 FY | 20 Million USD | 104.08% |
| 2018 Q1 | 12 Million USD | 22.45% |
| 2018 Q3 | 12 Million USD | 0.0% |
| 2018 Q4 | 20 Million USD | 66.67% |
| 2018 Q2 | 12 Million USD | 0.0% |
| 2017 FY | 9.8 Million USD | 139.02% |
| 2017 Q2 | 6.7 Million USD | 63.41% |
| 2017 Q1 | 4.1 Million USD | 0.0% |
| 2017 Q4 | 9.8 Million USD | 22.5% |
| 2017 Q3 | 8 Million USD | 19.4% |
| 2016 Q1 | 1.7 Million USD | 0.0% |
| 2016 FY | 4.1 Million USD | 141.18% |
| 2016 Q3 | 3.7 Million USD | 5.71% |
| 2016 Q2 | 3.5 Million USD | 105.88% |
| 2016 Q4 | 4.1 Million USD | 10.81% |
| 2015 Q2 | 1.7 Million USD | 0.0% |
| 2015 FY | 1.7 Million USD | 0.0% |
| 2015 Q4 | 1.7 Million USD | 0.0% |
| 2015 Q3 | 1.7 Million USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q2 | 5.85 Million USD | 34.4% |
| 2013 Q3 | 4.85 Million USD | -17.06% |
| 2013 Q4 | - USD | -100.0% |
| 2013 FY | - USD | -100.0% |
| 2013 Q1 | 4.35 Million USD | 0.0% |
| 2012 Q3 | 4.94 Million USD | 13.39% |
| 2012 Q4 | 4.35 Million USD | -11.81% |
| 2012 FY | 4.35 Million USD | -19.83% |
| 2012 Q1 | 6.55 Million USD | 34.98% |
| 2012 Q2 | 4.35 Million USD | -33.54% |
| 2011 Q2 | 6.42 Million USD | -9.5% |
| 2011 Q4 | 4.85 Million USD | -5.97% |
| 2011 Q3 | 5.16 Million USD | -19.6% |
| 2011 FY | 5.43 Million USD | -30.3% |
| 2011 Q1 | 7.1 Million USD | -0.79% |
| 2010 FY | 7.8 Million USD | -61.29% |
| 2010 Q2 | 13.99 Million USD | -9.89% |
| 2010 Q1 | 15.53 Million USD | -22.93% |
| 2010 Q3 | 8.04 Million USD | -42.49% |
| 2010 Q4 | 7.15 Million USD | -11.06% |
| 2009 Q1 | 7.26 Million USD | 6.37% |
| 2009 Q3 | 20.21 Million USD | 215.33% |
| 2009 Q2 | 6.4 Million USD | -11.72% |
| 2009 Q4 | 20.15 Million USD | -0.27% |
| 2009 FY | 20.15 Million USD | 195.28% |
| 2008 Q4 | 6.82 Million USD | 113.25% |
| 2008 Q3 | 3.2 Million USD | -12.53% |
| 2008 Q1 | 3.61 Million USD | -11.24% |
| 2008 Q2 | 3.65 Million USD | 1.15% |
| 2008 FY | 6.82 Million USD | 67.47% |
| 2007 Q3 | 4.53 Million USD | -9.18% |
| 2007 FY | 4.07 Million USD | -24.65% |
| 2007 Q2 | 4.99 Million USD | 0.84% |
| 2007 Q1 | 4.95 Million USD | -8.47% |
| 2007 Q4 | 4.07 Million USD | -10.11% |
| 2006 Q4 | 5.4 Million USD | 0.0% |
| 2006 FY | 5.4 Million USD | 1823.58% |
| 2005 FY | 281.2 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Harrow Health, Inc. | 190.5 Million USD | 90.326% |
| Dynavax Technologies Corporation | 256.91 Million USD | 92.827% |
| Biofrontera Inc. | 5.39 Million USD | -241.331% |
| DURECT Corporation | 20.74 Million USD | 11.171% |
| Cronos Group Inc. | 2.53 Million USD | -625.549% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 97.425% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 49.265% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -1471.048% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Radius Health, Inc. | 365.31 Million USD | 94.955% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -236.136% |
| ProPhase Labs, Inc. | 21.38 Million USD | 13.805% |
| Phibro Animal Health Corporation | 525.45 Million USD | 96.493% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -596.083% |
| Procaps Group S.A. | 285.93 Million USD | 93.555% |
| Alvotech | 1.07 Billion USD | 98.286% |
| TherapeuticsMD, Inc. | 8 Million USD | -130.212% |
| Rockwell Medical, Inc. | 13.43 Million USD | -37.127% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -2701.937% |
| Alpha Teknova, Inc. | 30.45 Million USD | 39.495% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -8.8% |
| SCYNEXIS, Inc. | 15.08 Million USD | -22.205% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -21.809% |
| Theratechnologies Inc. | 58.96 Million USD | 68.748% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 94.156% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -2931.0% |
| Safety Shot Inc | 1.54 Million USD | -1089.722% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 55.623% |
| SIGA Technologies, Inc. | 1.46 Million USD | -1158.768% |
| Tilray Brands, Inc. | 387.31 Million USD | 95.242% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 85.863% |
| Viatris Inc. | 18.12 Billion USD | 99.898% |
| PetIQ, Inc. | 468.3 Million USD | 96.065% |
| OptiNose, Inc. | 131.74 Million USD | 86.012% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 95.698% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -2701.937% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 84.559% |
| Alimera Sciences, Inc. | 67.39 Million USD | 72.658% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 97.267% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 40.91 Million USD | 54.956% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -1594.271% |
| Cosmos Health Inc. | 12.42 Million USD | -48.33% |
| Journey Medical Corporation | 17.73 Million USD | -3.94% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -122.658% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | -783.013% |
| Embecta Corp. | 1.63 Billion USD | 98.875% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -30713.254% |
| Procaps Group, S.A. | 285.93 Million USD | 93.555% |
| PainReform Ltd. | 86 Thousand USD | -21328.469% |
| Incannex Healthcare Limited | 373 Thousand USD | -4840.612% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -1683.778% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | 47.919% |
| Shineco, Inc. | 29.65 Million USD | 37.86% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 96.855% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 81.352% |
| Alvotech | 1.07 Billion USD | 98.286% |
| Hempacco Co., Inc. | 13.72 Million USD | -34.274% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | 70.498% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 97.013% |
| Bright Green Corporation | 1.85 Million USD | -895.175% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 96.593% |
| Kamada Ltd. | 8.74 Million USD | -110.636% |
| Indivior PLC | 281.6 Million USD | 93.456% |
| Evoke Pharma, Inc. | 5 Million USD | -268.57% |
| Flora Growth Corp. | 3.67 Million USD | -401.865% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -1683.778% |
| Evolus, Inc. | 126.54 Million USD | 85.437% |
| HUTCHMED (China) Limited | 86.13 Million USD | 78.604% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 97.045% |
| Akanda Corp. | 3.99 Million USD | -360.851% |